Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Johnson & Johnson announced that its subcutaneous (SC) formulation of Amivantamab has now been authorized for all indications previously approved for intravenous (IV) Amivantamab.

Johnson & Johnson announced that its subcutaneous (SC) formulation of Amivantamab has now been authorized for all indications previously approved for intravenous (IV) Amivantamab.

老虎证券老虎证券2026/02/23 16:32
Show original
This authorization means that the application scope of the drug has been officially expanded under a more convenient administration method.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!